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Hormone Replacement Therapy Appears to Be Safe After Prophylactic
Adnexectomy in Premenopausal BRCA1/BRCA2 Mutation Carriers
Reaction to the ‘Letter to readers’ in Hereditary Cancer in Clinical Practice, 2005, 3 (2)
Jan Lubiñski
In writing the letter to readers of our journal three months ago I was asking about opinions concerning the use
of hormone replacement therapy (HRT) in BRCA1/2 carriers after prophylactic adnexectomy, because at that
time it was practically impossible to present e ev vi id de en nc ce e- -b ba as se ed d   r re ec co om mm me en nd da at ti io on ns s. Actually, most of the responses
we have received have been opinions. It is important to recognise that the situation is now much clearer with
studies performed by Tim Rebbeck et al which are to be published in the J Jo ou ur rn na al l   o of f   C Cl li in ni ic ca al l   O On nc co ol lo og gy y. The
following responses have been received:
P Pr ro of f. .   H He en nr ry y   T T. .   L Ly yn nc ch h, ,   C Cr re ei ig gh ht to on n’ ’s s   H He er re ed di it ta ar ry y   C Ca an nc ce er r
I In ns st ti it tu ut te e; ;   D De ep pa ar rt tm me en nt t   o of f   P Pr re ev ve en nt ti iv ve e   M Me ed di ic ci in ne e, ,   C Cr re ei ig gh ht to on n
U Un ni iv ve er rs si it ty y   S Sc ch ho oo ol l   o of f   M Me ed di ic ci in ne e, ,   O Om ma ah ha a, ,   N NE E, ,   U US SA A, ,
h ht tl ly yn nc ch h@ @c cr re ei ig gh ht to on n. .e ed du u
My opinion about the use of HRT following
prophylactic surgeries in BRCA1 carriers remains a bit
controversial. Many confounders enter into the decision
making category. Most important is, in my opinion,
whether or not the patient has had any prior evidence
of carcinoma of the breast, age of onset, and of
course, whether there is so-called benign pathology
showing proliferative disease with atypia. 
I remain reluctant to advise HRT for any patients
with BRCA1 (or BRCA2 for that matter), unless the
woman is having significant postmenopausal type
problems, wherein quality of life becomes a major
issue. 
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m ma an ny y, ,   r ri it ta a. .s sc ch hm mu ut tz zl le er r@ @u uk k- -k ko oe el ln n. .d de e
As a coordinator of the German Hereditary Breast
and Ovarian Cancer Consortium I would like to
contribute our current strategy on HRT after prophylactic
salpingo-oophorectomy (PSO).
1. We advise PSO after completion of child-bearing
around the age of 40.
2.  Most mutation carriers decide to have this
procedure. The exact numbers will be available
soon.
3. We advise women that it may be beneficial to
abstain from HRT and that PSO without HRT may
result in an even higher risk reduction for breast
cancer (50% with HRT according to the Kauff and
Rebbeck data) although no clear data are available
yet. 
4. We discuss that we may substitute hormones if
postmenopausal complaints are unacceptable and
decrease quality of life considerably. Therefore we
see the patients on a regular basis after PSO in
order to record and discuss the side effects and
provide psychological support.
5.  We also offer participation in the IBIS2 trial
(prospective randomised trial on aromatase inhibitor
(AI) versus placebo).
6. In case of participation in the IBIS trial or abstention
from HRT we check osteoporosis risk factors and
may offer a Dexa scan possibly followed by
bisphosphonate substitution.
7. If patients do not want to be randomised and prefer
an additional medical prevention we offer tamoxifen.
M Mo on ni iq qu ue e   M M. .A A. .   B Br ro oo od d- -v va an n   Z Za an nt te en n, ,   M Ma ar ri iu us s   J J. .   v va an n
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Experimental data on the effects of hormone
therapy (HT) in women with BRCA1/2 mutations are
not available. HT is effective for flushes and vaginal
dryness. Theoretical models have calculated that use
of HT until the age of 50 after pBSO in women withH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 88
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BRCA1/2 mutations is associated with small changes
in life expectancy [1]. Colditz et al [2] found that HT
use does not further increase the risk of breast cancer
in high-risk women. HT should not be prescribed for
longer than 5 years. 
Breast density increases with combined
oestrogen/progestogen use, but does not change or
increases slightly with oestrogen alone or tibolone. 
A possible excess risk for breast cancer in high-risk
women with pBSO induced by HT is unknown.
Women who undergo pBSO are at risk of primary
peritoneal cancer, and it remains to be determined
whether HRT influences the risk of peritoneal cancer in
carriers of BRCA mutations.
C Co on ns si id de er ra at ti io on ns s
B BR RC CA A1 1/ /2 2  m mu ut ta at ti io on n  a an nd d  E ER R- -  s st ta at tu us s
BRCA1-related breast cancers are more frequently
oestrogen receptor (ER) negative than are either
BRCA2-related or non-hereditary breast cancers [3].
In particular, breast cancers occurring in older BRCA1
carriers are much more likely to be ER-negative than
are breast cancers developing in older non-carriers.
Only 3.9% of BRCA1-related breast cancers were ER-
positive cancers occurring in women in their
postmenopausal years.
B BR RC CA A1 1/ /2 2  m mu ut ta at ti io on n  a an nd d  m ma am mm mo og gr ra ap ph hy y
Breast density is high in women with a family history
of breast cancer [4]. Breast cancers are more difficult
to detect in dense breast tissue. 
There is a high prevalence of premalignant lesions
in BRCA1/2 carriers, especially after the age of 40 [5].
Mammography does not detect high-risk
histopathological lesions [6].
B BR RC CA A1 1/ /2 2  m mu ut ta at ti io on n  a an nd d  O OC C  u us se e
Among BRCA2 mutation carriers, use of oral
contraceptives was not associated with an increased
risk of breast cancer [7]. Compared with BRCA1
mutation carriers who never used oral contraceptives,
those who used oral contraceptives for at least 5 years
had an increased risk of breast cancer, although it
appears that oral contraceptive use after the age of 30
is not likely to increase the risk of breast cancer among
BRCA1 mutation carriers [8]. However, OC is
associated with a risk reduction for ovarian cancer [9],
possibly due to altered hormone receptor function [10]. 
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Following risk-reducing bilateral salpingo-
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BRCA2, without a personal history of breast cancer,
should make an informed personal decision about the
use of hormone replacement therapy (HRT), based on
her age, menopausal symptoms and personal/family
medical history. Overall, I believe that HRT post risk-
reducing BSO is not contraindicated under the age of
50 years; however, there are some difficulties
interpreting the literature. Oophorectomy prior to
menopause may be associated with a number of
adverse effects including significant menopausal
symptoms, unfavourable changes in lipid profile, an
increased risk of cardiovascular disease and an
increased risk of osteoporosis. I advise women that the
use of low dose HRT, until the age of 50, will not
increase their prior risk of breast cancer because HRT
will provide less oestrogen than her ovaries would have
provided up until the age of natural menopause. The
literature also suggests that HRT does not negate the
50% breast cancer risk reduction associated with
premenopausal BSO [1]. The use of HRT following risk-
reducing BSO is also supported by a recent decision
analysis. The model showed that prophylactic
oophorectomy, in women carrying a BRCA1/2
mutation, lengthened life expectancy by 3.34 to 4.65
years, depending on the age of oophorectomy; and
that the use of HRT showed very small reductions in the
life expectancy gains [2]. The fact that no data are
available about the actual affect of HRT on breast
cancer risk in BRCA1/2 carriers is one limitation of this
model [3]. Data from the Women’s Health Initiative
(WHI) suggest that the increased risk of breast cancer
appears to be limited to those receiving combined HRT
[4]; however, the option of hysterectomy and
unopposed oestrogen in premenopausal BRCA1/2
mutation carriers is controversial because there is
insufficient evidence to support this recommendation.
Although most BRCA1/2 mutation carriers over the age
of 50 will avoid HRT, some enquire about the short-
term use of HRT for relief of menopausal symptoms.
The Women’s Health Initiative (WHI) concludes that
short-term HRT is not associated with a significantly
increased risk of breast cancer; however, the ability to
extrapolate these data to BRCA1/2 mutation carriers
remains unclear.
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At the Familial Cancer Service at Westmead, our
advice to such women has evolved over the past ten
years. There is now good evidence that risk-reducing
salpingo-oophorectomy (RRSO) before the menopause
reduces the risk of both ovarian/fallopian tube cancer
and also of breast cancer. For this reason, our
unaffected female BRCA1/2 carriers are now strongly
advised that RRSO (+/- risk reducing mastectomy) is
the best option available at the current time to reduce
cancer risk. They are also informed of the lack of
proven efficacy of screening for ovarian cancer. RRSO
is suggested at the age of 35-40 for BRCA1 gene
mutation carriers, but is generally deferred until the
age of 40-45 in the case of BRCA2. This advice needs
to be individualised for carriers already affected by
breast cancer, depending on their age, time since
diagnosis and disease prognosis. RRSO may also be
considered to provide adjuvant therapy for pre-
menopausal BRCA carriers with a recent diagnosis of
hormone-dependant breast cancer.
In the period from 1996 until the present, we have
identified 34 BRCA1 carriers who are now aged ≥35
(suitable for RRSO), and who had one or both ovaries
intact at the time they received their genetic test result.
Of these, 44% have taken up the option of RRSO since
knowing their genetic status. Over the same time, 9
(36%) of 25 BRCA2 carriers now aged ≥40, with
ovaries intact at genetic testing, have taken up RRSO.
These figures include some women for whom a
diagnosis of breast cancer in the previous 5 years may
have impacted upon their decision. The uptake of
RRSO over the whole ten years is about 40% overall,
but on review, this has not increased recently, even with
the giving of stronger clinical advice.
In BRCA carriers choosing RRSO, who are
unaffected by breast cancer, the option of post-
operative HRT should be discussed. We agree with
Lubiñski that there is no evidence that HRT in such
cases is contra-indicated, though non-hormonalH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 90
alternatives can also be trialled in these women.
Management can be tailored to address specific
symptoms, such as hot flushes or vaginal dryness.
In Australia, over 12,000 individuals from almost
1000 high-risk breast/ovarian cancer kindreds are
currently enrolled in the national collaborative
kConFab (Kathleen Cuningham Foundation
CONsortium for research into FAmilial Breast cancer)
study. The study may eventually help to address the
question of safety and efficacy of HRT in high-risk
women. Importantly, the participants in the study have
indicated that provision of information about
management of symptoms following pre-menopausal
RRSO is an important issue for them. In response,
kConFab and Dr Peter Grant (Melbourne) have
addressed this need in a recent newsletter sent to all
participants (http://www.kconfab.org – see winter 2005
newsletter).
P Pr ro of f. .    S Sh hi ir rl le ey y    H Ho od dg gs so on n, ,    S St t    G Ge eo or rg ge e’ ’s s    H Ho os sp pi it ta al l
M Me ed di ic ca al l    S Sc ch ho oo ol l, ,    L Lo on nd do on n, ,    U Un ni it te ed d    K Ki in ng gd do om m, ,
s sh ho od dg gs so on n@ @s sg gu ul l. .a ac c. .u uk k
Usually we suggest oophorectomy with
salpingectomy ... on the whole I think many people do
give replacement oestrogens.
L Le en nk ka a    F Fo or re et to ov va a, ,    M Ma as sa ar ry yk k    M Me em mo or ri ia al l    C Ca an nc ce er r
I In ns st ti it tu ut te e, ,   B Br rn no o, ,   C Cz ze ec ch h   R Re ep pu ub bl li ic c, ,   f fo or re et to ov va a@ @m mo ou u. .c cz z
We have observed a low level of acceptance of
preventive adnexectomy in our BRCA1/2 carriers, who
are receiving follow-up in our high-risk clinic. All of
those women are informed by medical geneticists and
by gynaecologists about their increased risk of ovarian
cancer and about the problems with early detection
and are offered prophylactic surgery between 35 and
40 years of age. Only 40% of those eligible women
finally opt for surgical prevention. The reasons are
mostly the fear of complications in their marriage, in
their sexual life and other well-recognised problems
with oestrogen deficiency. In cases of continued refusal
the patients are asked to sign a ‘declaration’ to
indemnify the gynaecologist. 
The gynaecologist evaluates all women
individually and offers the HRT only to those who really
need it. Livial (tibolon) is a replacement choice, which
may have only a small effect on breast cancer risk. 
B Ba ar rb ba ar ra a    W We eb be er r, ,    T Tr ra an ns sl la at ti io on na al l    M Me ed di ic ci in ne e    a an nd d
G Ge en ne et ti ic cs s, ,   G Gl la ax xo oS Sm mi it th hK Kl li in ne e, ,   w we eb be er rb b@ @g gs sk k. .c co om m
I think it is essential to base such discussions on
data, not on opinions. We have both data and 
Jan Lubiñski
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a rationale to support the hypothesis that HRT
(particularly unopposed oestrogen) is safe for these
women, and MOST CERTAINLY safer than delaying
oophorectomy because of concerns about symptoms
of menopause. It is particularly important to note that
women with BRCA1 mutations who have intact ovaries
are not only at very high risk of developing ovarian
cancer, and substantially higher risk of breast cancer
than such women after oophorectomy, but producing
more ovarian hormones than provided by replacement
doses. I will send you a copy of our paper that has
been recently accepted by JCO. Enclosed please find
a slide explaining the rationale for this (Fig. 1).
T Ti im mo ot th hy y   R R. .   R Re eb bb be ec ck k, ,   P Ph h. .D D. ., ,   J Ji il ll l   E E. .   S St to op pf fe er r, ,   M M. .S S. ., ,
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P Ph hi il la ad de el lp ph hi ia a, ,   P PA A, ,   U US SA A
C CO OM MM ME EN NT TA AR RY Y: :    U US SE E    O OF F    H HO OR RM MO ON NE E
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B BR RC CA A2 2 M MU UT TA AT TI IO ON N   C CA AR RR RI IE ER RS S
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Bilateral risk-reducing oophorectomy (BRRO) is
widely used for cancer risk reduction in women with
BRCA1/2 mutations. BRRO significantly reduces breast
cancer risk by approximately 50% [1, 2] and ovarian
cancer risk by 85-95% [2-4]. An immediate
consequence of BRRO in premenopausal women is the
induction of surgical menopause, which can result in
severe hot flashes, vaginal dryness, sexual dysfunction,
sleep disturbances, and cognitive changes that may
affect quality of life [5]. Premature menopause is 
a significant risk factor for osteoporosis [6]. Thus, some
premenopausal women who undergo BRRO elect to
use at least short-term HRT to alleviate these symptoms.
Other mutation carriers may delay BRRO because of
concerns about HRT and breast cancer risk and remain
at high risk for ovarian cancer. As there are multiple
studies suggesting that HRT, particularly combined
oestrogen-progesterone use, increases risk of breast
cancer in postmenopausal women [7], there is
legitimate concern that HRT may offset the breast
cancer risk reduction conferred by BRRO. 
Importantly, these studies of HRT in postmenopausal
women are not directly applicable to premenopausal
women undergoing BRRO. For example, the median
age of the participants in the Women’s Health Initiative
(WHI) was over 60, well past the average age of
menopause in the United States, and participants were
included who had previously taken HRT [7, 8]. Most
importantly, the participants in the WHI were not
selected for premature menopause, and the vast
majority underwent non-surgical menopause. Despite
these limitations, the results of the WHI study are widely
known to patients and physicians and have led to 
a dramatic reduction in the use of hormone
replacement in postmenopausal women in the United
States [9]. However, the results of the WHI need to be
interpreted with caution when counselling BRCA1/2
mutation carriers undergoing premature, surgically
induced menopause for risk reduction purposes. 
Recently we reported that HRT of any type after
BRRO did not significantly alter the reduction in breast
cancer risk associated with BRRO in BRCA1/2 mutation
carriers. In this study, we prospectively examined 462
women with BRCA1/2 mutations and evaluated breast
cancer risk after BRRO with or without any HRT [3].
BRRO was associated with a significantly lower risk of
breast cancer (HR=0.40, 95% CI: 0.18-0.92) which
was not altered by the use of HRT (risk of breast cancer
HR=0.37, 95% CI: 0.14-0.96). These results
suggested that short-term HRT use does not negate the
protective effect of BRRO on subsequent breast cancer
risk in BRCA1/2 mutation carriers. While unanswered
questions remain regarding the use of HRT after BRRO,
such as the optimal type, duration and timing of HRT,
it is now possible to make reasonable decisions about
clinical management of women with BRCA1/2
mutations who have undergone BRRO. 
S Su ur rg gi ic ca al l   t ty yp pe e   a an nd d   i it ts s   i in nf fl lu ue en nc ce e   
o on n   p po os st t- -s su ur rg ge er ry y   H HR RT T   u us se e
A number of options are available to women with
BRCA1/2 mutations who are considering surgical risk
reduction. These include: a) bilateral salpingo-
oophorectomy (BSO) alone with combined
oestrogen/progesterone replacement; b) BSO alone
with short-term oestrogen only replacement,
considering the potential for an increased risk of uterine
cancer; c) total abdominal hysterectomy (TAH) with
BSO, followed by use of unopposed oestrogen; d) BSO
with or without TAH and without HRT.
There are numerous considerations to be made
when deciding among these and other possible
interventions. Women who carry BRCA1/2 mutationsH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 92
may wish to weigh the risks and benefits of TAH at the
time of BRRO using the following four considerations:
1) impact on HRT decisions; 2) uterine and cervical
cancer risk; 3) impact on decisions regarding
tamoxifen; 4) fallopian tube carcinoma risk. 
First, TAH allows women who are unaffected by
breast cancer to use unopposed oestrogen
replacement therapy rather than combined oestrogen
plus progesterone replacement therapy. This decision
has implications for the use of total abdominal
hysterectomy (TAH) at the time of BRRO, as use of
unopposed oestrogen in the absence of hysterectomy
is associated with an increased risk of endometrial
cancer (RR=2.3, 95% CI 2.1-2.5) [10]. Recent data
from the WHI demonstrated a significantly increased
risk of breast cancer among postmenopausal women
who took oestrogen and progesterone (HR=1.26, 95%
CI 1.00-1.59) [7], but not among women who took
oestrogen alone (HR=0.77, 95% CI 0.59-1.01) [8].
This difference is also supported by the results of the
Million Women Study, which found a two-fold increase
in breast cancer risk for users of oestrogen and
progesterone (RR=2.00, 95% CI 1.89-2.12) but 
a significantly lower risk for users of oestrogen alone
(RR=1.30, 95% CI 1.21-1.40) [11]. The effect of
unopposed oestrogen vs. combined oestrogen and
progesterone has not been well characterized in
BRCA1/2 mutation carriers, but based on the risk of
oestrogen and progesterone in the Million Women
Study, and the difference in the effect of oestrogen
alone compared to oestrogen and progesterone in the
WHI, the addition of progesterone remains a concern.
Therefore, undergoing a TAH at the time of BRRO
allows the use of oestrogen alone for HRT, which
minimizes potential breast cancer risk and eliminates
the endometrial cancer risk associated with unopposed
oestrogen exposure. 
Second, a number of reports suggest there is an
increased uterine and possibly cervical cancer risk in
BRCA1/2 mutation carriers (uterine cancer RR=2.65,
95% CI 1.69-4.16; cervical cancer RR=3.72, 95% CI
2.26-6.10) [12, 13]. Even though early detection of
these cancers is often possible, women already
planning to undergo BRRO may consider whether they
wish to eliminate uterine and cervical cancer risks by
undergoing TAH at the time of their BRRO. 
Third, tamoxifen has been shown to decrease the
risk of contralateral breast cancer in BRCA1/2 mutation
carriers (OR=0.50, 95% CI 0.28-0.89) [14]. Therefore,
tamoxifen use for prevention of breast cancer is 
a consideration for BRCA1/2 mutation carriers who
have completed HRT or who are not candidates for
HRT. The reported increased uterine cancer risk
associated with tamoxifen [15] is an additional
consideration for women contemplating TAH. 
Fourth, there is an excess risk of fallopian tube
carcinoma in BRCA1/2 mutation carriers compared to
the general population with an estimated relative risk of
over 100 [16]. Because a remnant of the fallopian tube
is left in the uterine wall at the time of BSO without TAH,
there is a theoretical benefit in considering TAH. However,
the absolute lifetime risk for the development of fallopian
tube cancer in mutation carriers is small (estimated at
3%) and there is currently very little information about the
occurrence of fallopian tube cancer among women who
have undergone BRRO without TAH.
If women consider having TAH in addition to BRRO,
the added risk and recovery time from TAH should be
considered. BRRO is an acceptable option in part
because surgical risks and recovery time are
outweighed by the benefit of a marked breast and
ovarian cancer risk reduction. However, the risk benefit
ratio for TAH in addition to BRRO is more complex,
both due to the small absolute advantages of TAH and
the potential for slightly higher morbidity associated
with this procedure. All of these elements must be
factored into the patient’s decision about the surgical
approach to cancer risk reduction. Women who are
likely to benefit most from having a TAH at the time of
BRRO are unaffected premenopausal women who will
also be faced with decisions on HRT and future
tamoxifen use. Women who are already
postmenopausal or who have had breast cancer will
not be considering issues of HRT and in these women
the potential benefits of TAH are likely to be very small. 
T Ty yp pe e   a an nd d   t ti im mi in ng g   o of f   p po os st t- -B BP PO O   H HR RT T   u us se e
Many women who undergo premenopausal BRRO
take HRT only until the age when they would have
experienced natural menopause, generally the age of
50. Since risk reduction for breast cancer increases the
earlier a woman has BRRO [2], many women consider
timing this surgery after childbearing decisions are
completed, often in their mid to late 30’s. Our recent
study [3] supports the decision to use short-term HRT
to manage immediate post-operative menopausal
symptoms, but does not address the potential that long-
term use may have very different implications for breast
cancer risk than long-term hormone exposure in
postmenopausal women. Furthermore, these results
are consistent with the results of a recent decision
analysis using hormone-associated risk data from the
recently published Women’s Health Initiative which
suggests that short-term use of HRT after
premenopausal BRRO is associated with little change
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in life expectancy, whereas the impact of long-term use
after the age of 50 is more substantial [17].
R Re ec co om mm me en nd da at ti io on ns s
Based upon the literature available to date, women
with BRCA1/2 mutations should be discouraged from
deferring BRRO because of fear of symptoms related
to surgical menopause and should be reassured that
use of short-term hormone replacement, if needed to
manage menopausal symptoms, does not negate the
breast cancer risk reduction from BRRO. BRRO, even
with short-term HRT, results in dramatic reductions in
both breast and ovarian cancer risk. 
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